Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 16/20 | 0.54 |
| ▸ | BRAF | P15056 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9973035 | 0.80 | CCR2 (0.63) | CCR2BRAF | |
| SCHEMBL9930920 | 0.80 | CCR2 (0.66) | CCR2BRAF | |
| SCHEMBL9930727 | 0.79 | CCR2 (0.57) | CCR2BRAFALDH1A1SMN1; SMN2 | |
| SCHEMBL9967890 | 0.77 | CCR2 (0.51) | CCR2BRAFALDH1A1SMN1; SMN2 | |
| SCHEMBL15477862 | 0.75 | CCR2 (0.60) | CCR2BRAF | |
| SCHEMBL16747603 | 0.75 | CCR2 (0.66) | CCR2BRAFALDH1A1SMN1; SMN2 | |
| SCHEMBL9931292 | 0.75 | CCR2 (0.69) | CCR2BRAFALDH1A1SMN1; SMN2 | |
| SCHEMBL9930936 | 0.74 | CCR2 (0.67) | CCR2BRAF | |
| SCHEMBL9930374 | 0.74 | CCR2 (0.79) | CCR2BRAF | |
| SCHEMBL9931076 | 0.74 | CCR2 (0.67) | CCR2BRAFALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157444-A1 | NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2012082633-A1 | NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157444-A1 | NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | CXCR2, CCR2, CX3CR1 | CCR2 2/4885BRAF 1188/4885ALDH1A1 2379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.